Cargando…

New drugs and new concerns: Gaining insight through Pharmacovigilance of direct acting Anti-Viral’s in chronic HCV patients

OBJECTIVE: The study aimed to assess the safety profile of Direct Acting Anti-Viral’s (DAAs) among patients with chronic Hepatitis C Virus (HCV). METHODS: This multicenter, analytical cross-sectional study was conducted in six gastroenterology and Hepatology centers including Liver Center Faisalabad...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hashmi, Zahid Yasin, Zia, Muhammad Qasim, Bajwa, Akram, Ahmed, Maqsood, Anwer, Naveed, Raza, Mahwish, Baqar, Jaffer Bin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Professional Medical Publications 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7931287/ https://www.ncbi.nlm.nih.gov/pubmed/33679903 http://dx.doi.org/10.12669/pjms.37.2.3400

Ejemplares similares

Exploring healthcare professionals’ knowledge, attitude, and practices towards pharmacovigilance: a cross-sectional survey
por: Hussain, Rabia, et al.
Publicado: (2021)

Fast-Growing Engineered Microbes: New Concerns for Gain-of-Function Research?
por: Pei, Lei, et al.
Publicado: (2018)

Assessment of Knowledge, Attitude and Barriers towards Pharmacovigilance among Physicians and Pharmacists of Abbottabad, Pakistan
por: Syed, Akash, et al.
Publicado: (2018)

Emergence and Persistence of Resistance-Associated Substitutions in HCV GT3 Patients Failing Direct-Acting Antivirals
por: Mushtaq, Saima, et al.
Publicado: (2022)

Seroprevalence and characteristics of Coronavirus Disease (COVID-19) in workers with non-specific disease symptoms
por: Javed, Wajiha, et al.
Publicado: (2022)

Effect of combined siRNA of HCV E2 gene and HCV receptors against HCV
por: Jahan, Shah, et al.
Publicado: (2011)

Barriers and facilitators to pharmacovigilance activities in Pakistan: A healthcare professionals-based survey
por: Hussain, Rabia, et al.
Publicado: (2022)

HCV entry receptors as potential targets for siRNA-based inhibition of HCV
por: Jahan, Shah, et al.
Publicado: (2011)

Prevalence of HCV genotypes in district Mardan
por: Afridi, Suliman Qadir, et al.
Publicado: (2013)

Pharmacovigilance
por: Griffin, J. P.
Publicado: (1992)

Safety Concerns with HPV Vaccines Continue to Linger: Are Current Vaccine Pharmacovigilance Practices Sufficient?
por: Chandler, Rebecca E.
Publicado: (2017)

Respiratory concerns of gabapentin and pregabalin: What does it mean to the pharmacovigilance systems in developing countries?
por: Shrestha, Sunil, et al.
Publicado: (2021)

HCV and kidney transplant in the era of new direct-acting antiviral agents (DAAs)
por: La Manna, Gaetano
Publicado: (2018)

Pharmacovigilance workflow in Europe and Italy and pharmacovigilance terminology
por: Baldo, Paolo, et al.
Publicado: (2018)

New anti HCV drugs in the pipeline
por: Bourlière, Marc
Publicado: (2010)

New drug interactions in HIV and HCV
por: Back, David
Publicado: (2012)

New anti-HCV agents in the pipeline
por: Zoulim, Fabien
Publicado: (2014)

A New Approach to Evaluating the Risk–Benefit Equation for Dual-Use and Gain-of-Function Research of Concern
por: Imperiale, Michael J., et al.
Publicado: (2018)

Determination of HCV genotypes and viral loads in chronic HCV infected patients of Hazara Pakistan
por: Ali, Amjad, et al.
Publicado: (2011)

A Fatal Case of Primary Orbital Ewing’s Sarcoma with Intracranial Extensions in a Six-year-old Girl
por: Raza, Natasha, et al.
Publicado: (2019)

Asymptomatic urinary tract infections and associated risk factors in Pakistani Muslim type 2 diabetic patients
por: Aamir, Azizul Hasan, et al.
Publicado: (2021)

A New Era in Pharmacovigilance: Toward Real‐World Data and Digital Monitoring
por: Lavertu, Adam, et al.
Publicado: (2021)

New adaptive lasso approaches for variable selection in automated pharmacovigilance signal detection
por: Courtois, Émeline, et al.
Publicado: (2021)

Dictionary of pharmacovigilance /
por: Alghabban, Amer
Publicado: (2004)

Pharmacovigilance in vaccines
por: Budhiraja, Salil, et al.
Publicado: (2010)

Pharmacovigilance and Pharmacoepidemiology
Publicado: (2008)

Challenges in pharmacovigilance
por: Dikshit, R. K.
Publicado: (2010)

Pharmacovigilance on olanzapine
por: Lingeswaran, Anand, et al.
Publicado: (2010)

Pharmacovigilance inspections
por: Fitzgerald, Patricia
Publicado: (2008)

Pharmacovigilance in Asia
por: Biswas, Pipasha
Publicado: (2013)

Pharmacovigilance in radiopharmaceuticals
por: Kumar, Rishi, et al.
Publicado: (2016)

Pharmacovigilance in oncology
por: Baldo, Paolo, et al.
Publicado: (2018)

Entry inhibitors: New advances in HCV treatment
por: Qian, Xi-Jing, et al.
Publicado: (2016)

New therapeutic options for HCV in Central Europe
por: Flisiak, Robert, et al.
Publicado: (2016)

New treatments for HCV: Perspective from Asia
por: Yu, Ming‐Lung, et al.
Publicado: (2015)

Under-reporting of adverse drug reactions: A challenge for pharmacovigilance in India
por: Tandon, Vishal R., et al.
Publicado: (2015)

The New Loves Gain the Day
Publicado: (1891)

New variant gains ground
por: Le Page, Michael
Publicado: (2021)

Promoter hypermethylation of Wnt pathway inhibitors in hepatitis C virus - induced multistep hepatocarcinogenesis
por: Umer, Muhammad, et al.
Publicado: (2014)

Heterogeneous distribution of HCV genotypes and growing menace of mixed HCV infection in blood recipients in Khyber Pakhtunkhwa
por: Attaullah, Sobia, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_gfvh0dct30dvjq4l4jcq68lbmd